Suppr超能文献

相似文献

1
Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules.
Cancer Immunol Immunother. 2006 Apr;55(4):355-62. doi: 10.1007/s00262-005-0081-y. Epub 2005 Sep 27.
3
The therapeutic potential of 4-1BB (CD137) in cancer.
Curr Cancer Drug Targets. 2005 Aug;5(5):357-63. doi: 10.2174/1568009054629681.
9
Immunobiology of tumor necrosis factor receptor superfamily.
Immunol Res. 2002;26(1-3):323-36. doi: 10.1385/IR:26:1-3:323.

引用本文的文献

1
Cholesterol restricts lymphotoxin β receptor-triggered NF-κB signaling.
Cell Commun Signal. 2019 Dec 26;17(1):171. doi: 10.1186/s12964-019-0460-1.
2
Toward Normalization of the Tumor Microenvironment for Cancer Therapy.
Integr Cancer Ther. 2019 Jan-Dec;18:1534735419862352. doi: 10.1177/1534735419862352.
3
Intratumoral immunotherapy for melanoma.
Cancer Immunol Immunother. 2015 Jul;64(7):911-21. doi: 10.1007/s00262-015-1727-z. Epub 2015 Jun 7.
5
Recombinant human CD19L-sTRAIL effectively targets B cell precursor acute lymphoblastic leukemia.
J Clin Invest. 2015 Mar 2;125(3):1006-18. doi: 10.1172/JCI76610. Epub 2015 Jan 26.
6
Predictive gene signature of response to the anti-TweakR mAb PDL192 in patient-derived breast cancer xenografts.
PLoS One. 2014 Nov 6;9(11):e104227. doi: 10.1371/journal.pone.0104227. eCollection 2014.
8
Lentivirus-mediated LIGHT overexpression inhibits human colorectal carcinoma cell growth and .
Oncol Lett. 2013 Oct;6(4):927-932. doi: 10.3892/ol.2013.1505. Epub 2013 Aug 1.
9
CD137 facilitates the resolution of acute DSS-induced colonic inflammation in mice.
PLoS One. 2013 Sep 4;8(9):e73277. doi: 10.1371/journal.pone.0073277. eCollection 2013.
10
Novel tumor suppressor function of glucocorticoid-induced TNF receptor GITR in multiple myeloma.
PLoS One. 2013 Jun 13;8(6):e66982. doi: 10.1371/journal.pone.0066982. Print 2013.

本文引用的文献

1
TNF/TNFR family members in costimulation of T cell responses.
Annu Rev Immunol. 2005;23:23-68. doi: 10.1146/annurev.immunol.23.021704.115839.
2
Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines.
Cancer Res. 2004 Nov 15;64(22):8411-9. doi: 10.1158/0008-5472.CAN-04-0590.
3
Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival.
Transpl Int. 2004 Aug;17(7):351-61. doi: 10.1007/s00147-004-0726-3. Epub 2004 Jul 31.
5
CD40/CD154 interactions at the interface of tolerance and immunity.
Annu Rev Immunol. 2004;22:307-28. doi: 10.1146/annurev.immunol.22.012703.104533.
6
Priming of naive T cells inside tumors leads to eradication of established tumors.
Nat Immunol. 2004 Feb;5(2):141-9. doi: 10.1038/ni1029. Epub 2004 Jan 4.
7
4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells.
J Leukoc Biol. 2004 May;75(5):785-91. doi: 10.1189/jlb.1003491. Epub 2003 Dec 23.
8
Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo.
Blood. 2004 Jan 1;103(1):177-84. doi: 10.1182/blood-2003-06-2184. Epub 2003 Sep 11.
9
Does the immune system see tumors as foreign or self?
Annu Rev Immunol. 2003;21:807-39. doi: 10.1146/annurev.immunol.21.120601.141135. Epub 2001 Dec 19.
10
T cells require TRAIL for optimal graft-versus-tumor activity.
Nat Med. 2002 Dec;8(12):1433-7. doi: 10.1038/nm1202-797. Epub 2002 Nov 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验